$REPL
Replimune Group, Inc. Stock $repl

$repl Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000173795322000005 Filed on February 03, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.25M	$10.35M	$9.345M
YoY Change	72.01%	76.54%	69.29%
% of Gross Profit
Research & Development	$21.22M	$19.35M	$19.90M
YoY Change	35.07%	35.13%	41.65%
% of Gross Profit
Depreciation & Amortization	$549.0K	$548.0K	$532.0K
YoY Change	12.04%	36.32%	25.18%
% of Gross Profit
Operating Expenses	$31.99M	$29.70M	$29.25M
YoY Change	44.22%	46.48%	48.74%
Operating Profit		-$29.70M	-$29.25M
YoY Change		46.48%	48.74%
Interest Expense	-$422.0K	-$468.0K	-$477.0K
YoY Change	-10.21%	-32.17%	-28.81%
% of Operating Profit
Other Income/Expense, Net	$714.0K	$24.00K	-$108.0K
YoY Change	-37.91%	-101.59%	-75.0%
Pretax Income	-$31.70M	-$29.67M	-$29.36M
YoY Change	47.42%	36.24%	46.04%
Income Tax
% Of Pretax Income
Net Earnings	-$31.70M	-$29.67M	-$29.36M
YoY Change	47.42%	36.23%	46.08%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.57	-$0.56
Diluted Earnings Per Share	-$603.3K	-$0.57	-$0.56
COMMON SHARES
Basic Shares Outstanding	47.21M shares	52.32M shares	52.08M shares
Diluted Shares Outstanding		52.32M shares	52.08M shares

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$395.7M	$420.2M	$435.8M
YoY Change	-16.93%	-14.82%	78.16%
Cash & Equivalents	$105.9M	$132.3M	$160.0M
Short-Term Investments	$289.7M	$287.9M	$275.8M
Other Short-Term Assets	$5.267M	$5.413M	$5.726M
YoY Change	17.04%	35.33%	21.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$404.0M	$427.8M	$444.4M
YoY Change	-16.49%	-14.34%	76.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.933M	$7.412M	$7.178M
YoY Change	6.6%	-87.24%	-87.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.636M	$1.636M	$1.636M
YoY Change	2.25%	2.25%	2.25%
Total Long-Term Assets	$57.22M	$57.49M	$59.08M
YoY Change	-3.6%	-3.87%	-4.4%
TOTAL ASSETS
Total Short-Term Assets	$404.0M	$427.8M	$444.4M
Total Long-Term Assets	$57.22M	$57.49M	$59.08M
Total Assets	$461.2M	$485.3M	$503.5M
YoY Change	-15.08%	-13.22%	60.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.732M	$3.922M	$3.154M
YoY Change	58.47%	63.42%	31.42%
Accrued Expenses	$13.14M	$10.90M	$10.06M
YoY Change	42.85%	41.55%	39.68%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.562M	$2.543M	$2.524M
YoY Change	2.48%	1.72%	0.96%
Total Short-Term Liabilities	$20.76M	$18.29M	$16.64M
YoY Change	42.68%	40.7%	27.97%
LONG-TERM LIABILITIES
Long-Term Debt	$24.41M	$24.50M	$24.59M
YoY Change	-1.19%	-1.21%	-29.12%
Other Long-Term Liabilities	$4.801M	$4.981M	$4.822M
YoY Change	-5.86%	-4.21%	-7.27%
Total Long-Term Liabilities	$29.21M	$29.48M	$29.42M
YoY Change	-1.99%	-1.73%	-26.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.76M	$18.29M	$16.64M
Total Long-Term Liabilities	$29.21M	$29.48M	$29.42M
Total Liabilities	$49.96M	$47.77M	$46.05M
YoY Change	12.61%	11.1%	-12.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$311.2M	-$279.5M	-$249.8M
YoY Change	61.11%
Common Stock	$47.00K	$47.00K	$47.00K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$411.2M	$437.5M	$457.4M
YoY Change
Total Liabilities & Shareholders Equity	$461.2M	$485.3M	$503.5M
YoY Change	-15.08%	-13.22%	60.24%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q3
OPERATING ACTIVITIES
Net Income	-$31.70M	-$29.67M	-$29.36M
YoY Change	47.42%	36.23%	46.08%
Depreciation, Depletion And Amortization	$549.0K	$548.0K	$532.0K
YoY Change	12.04%	36.32%	25.18%
Cash From Operating Activities	-$22.56M	-$18.35M	-$22.96M
YoY Change	39.85%	41.25%	33.65%
INVESTING ACTIVITIES
Capital Expenditures	-$1.152M	-$465.0K	-$428.0K
YoY Change	49.61%	-23.77%	435.0%
Acquisitions
YoY Change
Other Investing Activities	-$3.174M	-$12.95M	-$10.62M
YoY Change	-97.47%	-140.43%	-76.25%
Cash From Investing Activities	-$4.326M	-$13.42M	-$11.05M
YoY Change	-96.57%	-142.71%	-75.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	359.0K	3.969M	1.150M
YoY Change	-53.97%	-98.49%	-3933.33%
NET CHANGE
Cash From Operating Activities	-22.56M	-18.35M	-22.96M
Cash From Investing Activities	-4.326M	-13.42M	-11.05M
Cash From Financing Activities	359.0K	3.969M	1.150M
Net Change In Cash	-26.52M	-27.80M	-32.86M
YoY Change	-81.27%	-109.91%	-47.0%
FREE CASH FLOW
Cash From Operating Activities	-$22.56M	-$18.35M	-$22.96M
Capital Expenditures	-$1.152M	-$465.0K	-$428.0K
Free Cash Flow	-$21.41M	-$17.88M	-$22.53M
YoY Change	39.36%	44.45%	31.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001737953
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 Unicorn Park
	dei	Entity Address City Or Town EntityAddressCityOrTown	Woburn
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y9M18D
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38596
	dei	Entity Registrant Name EntityRegistrantName	REPLIMUNE GROUP, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2082553
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01801
	dei	City Area Code CityAreaCode	781
	dei	Local Phone Number LocalPhoneNumber	222-9600
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47209545	shares
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132275000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	182518000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	287897000	USD
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	REPL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	us-gaap	Short Term Investments ShortTermInvestments	293784000	USD
CY2021Q4	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	2210000	USD
CY2021Q1	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	2953000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5413000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4492000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	427795000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	483747000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7412000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7442000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1636000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1636000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5738000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5751000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	42701000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	44522000	USD
CY2021Q4	us-gaap	Assets Assets	485282000	USD
CY2021Q1	us-gaap	Assets Assets	543098000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3922000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2355000	USD
	us-gaap	Operating Expenses OperatingExpenses	57771000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	10754000	USD
CY2021Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8735000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1072000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	970000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2543000	USD
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2487000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18291000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14547000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4981000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5078000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24501000	USD
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24745000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	47773000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	44370000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47206316	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47206316	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46566481	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46566481	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	47000	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	47000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	717151000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	692243000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-279508000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-193168000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-181000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17242000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-394000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	437509000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	498728000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	485282000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	543098000	USD
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19353000	USD
CY2020Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14322000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57809000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40529000	USD
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10345000	USD
CY2020Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5953000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28517000	USD
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	29698000	USD
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	20275000	USD
	us-gaap	Operating Expenses OperatingExpenses	86326000	USD
CY2020Q4	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	116000	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	259000	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	821000	USD
CY2021Q4	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	555000	USD
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-29698000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-20275000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-86326000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-57771000	USD
CY2021Q4	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	733000	USD
CY2020Q4	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	550000	USD
	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	2246000	USD
	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	1991000	USD
CY2021Q4	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	87000	USD
CY2020Q4	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	560000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1670000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1683000	USD
CY2021Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2020Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	247000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	817000	USD
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-913000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-913000	USD
CY2021Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-241000	USD
CY2020Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-454000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-849000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-999000	USD
CY2021Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	24000	USD
CY2020Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1508000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1600000	USD
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29674000	USD
CY2020Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21783000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-86340000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-59371000	USD
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52319877	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52319877	shares
CY2020Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49382213	shares
CY2020Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49382213	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52104548	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52104548	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44436680	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44436680	shares
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-29674000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-21783000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-86340000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-59371000	USD
CY2021Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	161000	USD
CY2020Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	548000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	604000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1162000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2021Q4	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-351000	USD
CY2020Q4	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-53000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-391000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	479024000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	219000	USD
	repl	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-341000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-62503000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-296000	USD
CY2021Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29864000	USD
CY2020Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21288000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-86127000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58505000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	498728000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	224000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-40000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1173000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6250000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-27311000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1211000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6313000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-29355000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	457412000	USD
CY2021Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	161000	USD
CY2021Q4	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-351000	USD
CY2021Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4043000	USD
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5918000	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-29674000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	437509000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	183718000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	32900000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	74882000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-12000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-196000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1547000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2468000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-17493000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	277814000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	626000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-47000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	291000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2801000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-20095000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	261390000	USD
CY2020Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	548000	USD
CY2020Q4	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-53000	USD
CY2020Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3069000	USD
CY2020Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	58750000	USD
CY2020Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	13775000	USD
CY2020Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	211225000	USD
CY2020Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3049000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-21783000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	516195000	USD
	us-gaap	Profit Loss ProfitLoss	-86340000	USD
	us-gaap	Profit Loss ProfitLoss	-59371000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	18481000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8318000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1598000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1217000	USD
	repl	Net Amortization Of Premiums And Discounts On Short Term Investments NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments	-1792000	USD
	repl	Net Amortization Of Premiums And Discounts On Short Term Investments NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments	-841000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	181000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-913000	USD
	repl	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	-700000	USD
	repl	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	-1078000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	934000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1238000	USD
	repl	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	29000	USD
	repl	Increase Decrease Finance Lease Right Of Use Asset IncreaseDecreaseFinanceLeaseRightOfUseAsset	-1821000	USD
	repl	Increase Decrease Finance Lease Right Of Use Asset IncreaseDecreaseFinanceLeaseRightOfUseAsset	-1795000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1193000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1018000	USD
	repl	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	2047000	USD
	repl	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	1919000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	48000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-237000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59623000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45261000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1184000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1622000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	192546000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	225029000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	196250000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	164148000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2520000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6427000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	100000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	286107000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	91650000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	10000000	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	795000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	188000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	92000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4907000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6239000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	371677000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	621000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1062000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50243000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	264975000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184154000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61136000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	133911000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	326111000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	636000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	55000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	491000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	491000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	99000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	365000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	365000	USD
CY2019Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	85598000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1580000	USD
	us-gaap	Nature Of Operations NatureOfOperations	Nature of the business<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Replimune Group, Inc. (the “Company”) is a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through our novel tumor-directed oncolytic immunotherapies. Our proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Replimune Group, Inc., whose predecessor was founded in 2015, is the parent company of its wholly owned, direct and indirect subsidiaries: Replimune Limited (“Replimune UK”); Replimune, Inc. (“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net losses of $29,674 and $21,783 for the three months ended December 31, 2021 and 2020, respectively, and net losses of $86,340 and $59,371 for the nine months ended December 31, 2021 and 2020, respectively. In addition, as of December 31, 2021, the Company had an accumulated deficit of $279,508. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of these consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 coronavirus</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus, which causes the disease known as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 coronavirus has spread globally and recently identified variants of COVID-19, Delta and Omicron, which appear to be more transmissible and contagious than previous COVID-19 variants, have caused an increase in the number of COVID-19 cases globally. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic and the U.S. government imposed travel restrictions on travel between the United States, Europe and certain other countries. The impact of this pandemic has been, and may continue to be, extensive in many aspects of society, which has resulted, and may continue to result, in significant disruptions to the global economy as well as businesses and capital markets around the world.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company has taken precautionary measures, including implementing work-from-home policies for the Company’s employees, other than those in its laboratory, those performing manufacturing functions and certain other employees as deemed appropriate from time to time. For those employees, the Company has implemented stringent safety measures designed to comply with applicable federal, state and local guidelines instituted in response to the COVID-19 pandemic. The Company continues to evolve its work-from-home policies toward return-to-office policies, as applicable under the circumstances while following local, state and federal guidelines and safety practices. The Company has taken these and other precautionary steps while maintaining business continuity in order to continue to progress its programs. While there has been no prolonged material disruption to the Company’s business to date, the impact of the virus, including work-from-home policies, may negatively impact productivity, disrupt the Company’s business, and delay its preclinical research and clinical trial activities and its development program timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct its business in the ordinary course. Other impacts to the Company’s business may include temporary closures of its suppliers and disruptions or restrictions on its employees’ ability to travel. Any </span></div>prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s preclinical research and clinical trial activities, financial condition and results of operations, including its ability to obtain financing.
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-29674000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-21783000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-86340000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-59371000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-279508000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic, including evolving COVID-19 viral strains, will directly or indirectly impact our business, results of operations and financial condition, including, expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</span></div>
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11658000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10090000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4246000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2648000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7412000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7442000	USD
CY2021Q4	us-gaap	Depreciation Depreciation	548000	USD
	us-gaap	Depreciation Depreciation	1598000	USD
CY2020Q4	us-gaap	Depreciation Depreciation	402000	USD
	us-gaap	Depreciation Depreciation	1217000	USD
CY2021Q4	repl	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	4845000	USD
CY2021Q1	repl	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	3862000	USD
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4509000	USD
CY2021Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3952000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	473000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	407000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	927000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	514000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	10754000	USD
CY2021Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8735000	USD
CY2019Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5814000	USD
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107782000	USD
CY2020Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	269975000	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5284238	shares
CY2021Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5918000	USD
CY2020Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3049000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18481000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	125000000	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8318000	USD
CY2021Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5918000	USD
CY2020Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3049000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18481000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8318000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0112
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0101
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.800
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.748
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1072000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	970000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.05
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14552000	USD
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6460184	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.26
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M12D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	116193000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1476507	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	32.09
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	639835	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	601469	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	26.24
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6695387	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.55
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M8D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	81838000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2698708	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.38
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M14D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	59717000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3492076	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.96
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y5M19D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	60493000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	21.95
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.06
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14600000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-59371000	USD
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52319877	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52319877	shares
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29674000	USD
CY2020Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21783000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-86340000	USD
CY2020Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49382213	shares
CY2020Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49382213	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52104548	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52104548	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44436680	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44436680	shares
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7192731	shares
CY2021Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7192731	shares
CY2020Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6823921	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6823921	shares
CY2021Q4	repl	Lessee Operating Lease Rentable Area LesseeOperatingLeaseRentableArea	2951	sqft
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2021Q4	repl	Operating Lease Annual Lease Payments OperatingLeaseAnnualLeasePayments	100000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	400000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	400000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	607000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	607000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1821000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1821000	USD
CY2021Q4	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	555000	USD
CY2020Q4	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	560000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1670000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1683000	USD
CY2021Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	249000	USD
CY2020Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	239000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	736000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	705000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	607000	USD
CY2021Q4	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	555000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1821000	USD
CY2021Q4	us-gaap	Lease Cost LeaseCost	1411000	USD
CY2020Q4	us-gaap	Lease Cost LeaseCost	1406000	USD
	us-gaap	Lease Cost LeaseCost	4227000	USD
	us-gaap	Lease Cost LeaseCost	4209000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	607000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1821000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1670000	USD
CY2020Q4	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	560000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1683000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	260000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	629000	USD
CY2021Q4	repl	Operating And Finance Lease Liability Payments Remainder Of Fiscal Year OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	889000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1083000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2562000	USD
CY2021Q4	repl	Operating And Finance Lease Liability Payments Due Next Twelve Months OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3645000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1093000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2639000	USD
CY2021Q4	repl	Operating And Finance Lease Liability Payments Due Year Two OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo	3732000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1102000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	2718000	USD
CY2021Q4	repl	Operating And Finance Lease Liability Payments Due Year Three OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree	3820000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1111000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	2799000	USD
CY2021Q4	repl	Operating Finance Lease Liability Payments Due Year Four OperatingFinanceLeaseLiabilityPaymentsDueYearFour	3910000	USD
CY2021Q4	repl	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	4095000	USD
CY2021Q4	repl	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	40905000	USD
CY2021Q4	repl	Operating And Finance Lease Liability Payments Due After Year Four OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour	45000000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6053000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	27044000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8744000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	52252000	USD
CY2021Q4	repl	Operating And Finance Lease Liability Payments Due OperatingAndFinanceLeaseLiabilityPaymentsDue	60996000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2691000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	25208000	USD
CY2021Q4	repl	Operating And Finance Lease Liability Undiscounted Excess Amount OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount	27899000	USD
CY2021Q4	repl	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	33097000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5738000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5751000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	42701000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	44522000	USD
CY2021Q4	repl	Lease Right Of Use Asset LeaseRightOfUseAsset	48439000	USD
CY2021Q1	repl	Lease Right Of Use Asset LeaseRightOfUseAsset	50273000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2543000	USD
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2487000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4981000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5078000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24501000	USD
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24745000	USD
CY2021Q4	repl	Lease Liability LeaseLiability	33097000	USD
CY2021Q1	repl	Lease Liability LeaseLiability	33280000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	648000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	582000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1670000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1683000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	188000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	92000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	365000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1580000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y10M24D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P17Y7M6D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P18Y7M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.102
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.098
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.083
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.083
CY2021Q4	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1190000	USD
CY2021Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1651000	USD
	repl	Number Of Operating Geographic Regions NumberOfOperatingGeographicRegions	2	region
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	7412000	USD
CY2021Q1	us-gaap	Noncurrent Assets NoncurrentAssets	7442000	USD

Files In Submission

Name	View Source	Status
0001737953-22-000005-index-headers.html	Edgar Link	pending
0001737953-22-000005-index.html	Edgar Link	pending
0001737953-22-000005.txt	Edgar Link	pending
0001737953-22-000005-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
repl-123121x10qxex311.htm	Edgar Link	pending
repl-123121x10qxex312.htm	Edgar Link	pending
repl-123121x10qxex321.htm	Edgar Link	pending
repl-123121x10qxex322.htm	Edgar Link	pending
repl-20211231.htm	Edgar Link	pending
repl-20211231.xsd	Edgar Link	pending
repl-20211231_cal.xml	Edgar Link	unprocessable
repl-20211231_def.xml	Edgar Link	unprocessable
repl-20211231_g1.jpg	Edgar Link	pending
repl-20211231_htm.xml	Edgar Link	completed
repl-20211231_lab.xml	Edgar Link	unprocessable
repl-20211231_pre.xml	Edgar Link	unprocessable
replimunelimited_miltonp.htm	Edgar Link	pending
replimunelimited_miltonp001.jpg	Edgar Link	pending
replimunelimited_miltonp002.jpg	Edgar Link	pending
replimunelimited_miltonp003.jpg	Edgar Link	pending
replimunelimited_miltonp004.jpg	Edgar Link	pending
replimunelimited_miltonp005.jpg	Edgar Link	pending
replimunelimited_miltonp006.jpg	Edgar Link	pending
replimunelimited_miltonp007.jpg	Edgar Link	pending
replimunelimited_miltonp008.jpg	Edgar Link	pending
replimunelimited_miltonp009.jpg	Edgar Link	pending
replimunelimited_miltonp010.jpg	Edgar Link	pending
replimunelimited_miltonp011.jpg	Edgar Link	pending
replimunelimited_miltonp012.jpg	Edgar Link	pending
replimunelimited_miltonp013.jpg	Edgar Link	pending
replimunelimited_miltonp014.jpg	Edgar Link	pending
replimunelimited_miltonp015.jpg	Edgar Link	pending
replimunelimited_miltonp016.jpg	Edgar Link	pending
replimunelimited_miltonp017.jpg	Edgar Link	pending
replimunelimited_miltonp018.jpg	Edgar Link	pending
replimunelimited_miltonp019.jpg	Edgar Link	pending
replimunelimited_miltonp020.jpg	Edgar Link	pending
replimunelimited_miltonp021.jpg	Edgar Link	pending
replimunelimited_miltonp022.jpg	Edgar Link	pending
replimunelimited_miltonp023.jpg	Edgar Link	pending
replimunelimited_miltonp024.jpg	Edgar Link	pending
replimunelimited_miltonp025.jpg	Edgar Link	pending
replimunelimited_miltonp026.jpg	Edgar Link	pending
replimunelimited_miltonp027.jpg	Edgar Link	pending
replimunelimited_miltonp028.jpg	Edgar Link	pending
replimunelimited_miltonp029.jpg	Edgar Link	pending
replimunelimited_miltonp030.jpg	Edgar Link	pending
replimunelimited_miltonp031.jpg	Edgar Link	pending
replimunelimited_miltonp032.jpg	Edgar Link	pending
replimunelimited_miltonp033.jpg	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REPL
Replimune Group, Inc. Stock $repl

2022 Q1 Form 10-Q Financial Statement

#000173795322000005 Filed on February 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REPL Replimune Group, Inc. Stock $repl

2022 Q1 Form 10-Q Financial Statement

#000173795322000005 Filed on February 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REPL
Replimune Group, Inc. Stock $repl